Background: Combining bevacizumab with platinum-based chemotherapy significantly improves survival for patients with advanced non-squamous non-small cell lung cancer. The objective of this study was to assess the proportion of patients who could receive this combined therapy.
Methods: This was a retrospective single centre analysis of patients treated between 2007 and 2008.